NEW YORK, March 5 -- John Carpenter, the co-founder of the University of Colorado's center for pharmaceutical biotechnology, and Joshua Wand, chair of the University of Pennsylvania's graduate group in biochemistry and molecular biophysics, have been appointed to the scientific advisory board of Houston-based proteomic informatics company RedStorm Scientific, the company said today.
Carpenter, an associate professor of pharmaceutical sciences at Colorado, conducts research to identify mechanisms for protein degradation and stabilization in pharmaceutical formulas and delivery systems, as well as in human disease.
Wand studies relatisonships between protein structural dynamics, static structure, and function; and has developed new NMR methodologies.
Reid Adler, general counsel to the J. Craig Venter Science Foundation, has been elected to the National Technology Transfer Center (NTTC) Advisory Board, the center announced today.
Adler will serve a three-year term on the board of the Wheeling, WV-based NTTC, which was established by Congress in 1989.
In his current position, Adler serves as chief legal and risk management officer for the Institute for Genomic Research, the Institute for Biological Energy Alternatives and the Center for Advancement of
Genomics. Previously, he has been a partner at Morgan, Lewis & Bockius in
Ralph Snyderman, president of the Duke University Health System and the leader in the development of genomic-based predictive medicine research at the university, plans to step down in June 2004 to return to academia, the unversity reported March 4.
Snyderman told a university newspaper he would still be committed to forging ahead with new prevention-oriented models of health care, and to help with development of the University's Institute for Genome Sciences and Policy.
Snyderman's announced resignation follows closely that of Duke president Nan Keohane, who said last Sunday that she would step down in 2004.
Snyderman has been on the Duke faculty since 1973, and has conducted pioneering research into the leukocyte cell signaling in response to tissue damage. He was appointed dean of the Duke University School of Medicine in 1989.
The National Disease Research Interchange plans to name Eric Lander of MIT's Whitehead Institute scientist of the year, the association announced March 3.
Lander, who is being recognized for his leadership in genomic research, will accept the award at the association's March 25 conference in